Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cortes

Showing results (101-110 of 231) with videos related to

Pageof 24
Sort By:
Future Oncology (London, England)|September 1, 2021
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancerAditya Bardia, Sara A Hurvitz, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxanePeter A Kaufman, Ahmad Awada, Chris Twelves, et al.
BMC Cancer|August 23, 2023
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysisJavier Cortes, Amin Haiderali, Min Huang, et al.
The Oncologist|May 15, 2024
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trialHope S Rugo, Peter Schmid, Sara M Tolaney, et al.
Breast Cancer Research and Treatment|July 13, 2022
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancerErika Hamilton, Javier Cortes, Ozgur Ozyilkan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004George Somlo, Francesco Atzori, Lewis C Strauss, et al.
Journal of the National Cancer Institute|April 19, 2007
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerMaurizio Scaltriti, Federico Rojo, Alberto Ocaña, et al.
Cancer Treatment Reviews|May 22, 2024
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancerLuca Licata, Maria Vittoria Dieci, Carmine De Angelis, et al.
Breast Cancer Research : BCR|July 9, 2016
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapyChristopher Twelves, Javier Cortes, Peter A Kaufman, et al.
Breast Cancer (Tokyo, Japan)|March 6, 2020
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE studyYasuo Miyoshi, Yuta Yoshimura, Kenichi Saito, et al.
Pageof 24

Showing results (101-110 of 231) with videos related to

Sort By:
Pageof 24
Future Oncology (London, England)|September 1, 2021
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancerAditya Bardia, Sara A Hurvitz, Hope S Rugo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxanePeter A Kaufman, Ahmad Awada, Chris Twelves, et al.
BMC Cancer|August 23, 2023
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysisJavier Cortes, Amin Haiderali, Min Huang, et al.
The Oncologist|May 15, 2024
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trialHope S Rugo, Peter Schmid, Sara M Tolaney, et al.
Breast Cancer Research and Treatment|July 13, 2022
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancerErika Hamilton, Javier Cortes, Ozgur Ozyilkan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2013
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004George Somlo, Francesco Atzori, Lewis C Strauss, et al.
Journal of the National Cancer Institute|April 19, 2007
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerMaurizio Scaltriti, Federico Rojo, Alberto Ocaña, et al.
Cancer Treatment Reviews|May 22, 2024
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancerLuca Licata, Maria Vittoria Dieci, Carmine De Angelis, et al.
Breast Cancer Research : BCR|July 9, 2016
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapyChristopher Twelves, Javier Cortes, Peter A Kaufman, et al.
Breast Cancer (Tokyo, Japan)|March 6, 2020
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE studyYasuo Miyoshi, Yuta Yoshimura, Kenichi Saito, et al.
Pageof 24